Echo IQ deploys AI aortic stenosis tool at top-ranked Mount Sinai Health System

EchoIQ Limited ( (AU:EIQ) ) has issued an update.

Echo IQ has deployed its EchoSolv AS decision support software for severe aortic stenosis into New York’s Mount Sinai Health System, which includes seven hospitals, more than 400 outpatient practices and a top-ranked cardiovascular program. The rollout places EchoSolv AS within a high-volume, research-focused cardiac network, aligning Echo IQ with one of the U.S. leaders in cardiology and digital health adoption.

Management describes the Mount Sinai agreement as a major milestone in its U.S. commercial strategy, aimed at embedding AI tools into routine echocardiography and building traction with prominent cardiovascular institutions. Echo IQ expects the collaboration to reinforce its growth trajectory by expanding hospital partnerships, supporting large-scale clinical use and opening avenues for further product development and research in AI-enabled cardiac care.

The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$1.30 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.

More about EchoIQ Limited

Echo IQ Limited is a Sydney-based AI and medical technology company that develops proprietary software to improve decision-making in cardiology. Its flagship product, EchoSolv AS, is an AI-driven decision support tool designed to assist qualified healthcare professionals in assessing severe aortic stenosis as an adjunct to standard echocardiography workflows.

Average Trading Volume: 2,942,836

Technical Sentiment Signal: Buy

Current Market Cap: A$773.2M

For detailed information about EIQ stock, go to TipRanks’ Stock Analysis page.